# Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

> **NCT04115761** · PHASE2 · RECRUITING · sponsor: **Ever Supreme Bio Technology Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- GBM

## Interventions

- **BIOLOGICAL:** autologous dendritic cells

## Key facts

- **NCT ID:** NCT04115761
- **Lead sponsor:** Ever Supreme Bio Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-06
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115761, "Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04115761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*